Low plasma renin activity and high aldosterone/renin ratio are associated with untreated isolated systolic hypertension

Blood Pressure

Volumn 21, Issue 5, 2012, Pages 320-325

  Durukan, Mine ^a   Guray, Umit ^b   Aksu, Tolga ^b   Guray, Yesim ^b   Demirkan, Burcu ^b   Korkmaz, Sule ^b  

^a TOROS UNIVERSITY   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Aldosterone; Aldosterone renin ratio; Isolated systolic hypertension; Plasma renin activity

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; RENIN;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; HUMAN; ISOLATED SYSTOLIC HYPERTENSION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

AGED; ALDOSTERONE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SYSTOLE;

EID: 84866900007     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2012.686167     Document Type: Article

References (26)

1. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D ' Agostino RB, et al. Residual lifetime risk for developinghypertension in middle-aged women and men: The FraminghamHeart Study. JAMA. 2002;287:1003-1010.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, GreenLA, Izzo JL Jr, et al.; National Heart, Lung, and Blood InstituteJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; NationalHigh Blood Pressure Education Program CoordinatingCommittee. The Seventh Report of the Joint National Committeeon Prevention, Detection, Evaluation, and Treatmentof High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
3. Lakatta EG. Central arterial aging and the epidemic of systolichypertension and atherosclerosis. J Am Soc Hypertens. 2007;1:302-340.
4. Chobanian AV. Clinical practice. Isolated systolic hypertensionin the elderly. N Engl J Med. 2007;357:789-796.
5. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. Guidelines for management ofhypertension: Report of the third working party of the BritishHypertension Society. J Hum Hypertens. 1999;13:569-592.
6. SHEP Cooperative Research Group. Prevention of stroke byantihypertensive drug treatment in older persons with isolatedsystolic hypertension: Final results of the systolic hypertensionin the elderly program. JAMA. 1991;265:3255-3265.
7. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double blind comparisonof placebo and active treatment for older patients with isolatedsystolic hypertension. Lancet. 1997;350:757-764.
8. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin- aldosterone system. J Renin Angiotensin AldosteroneSyst. 2004;5:102-108.
9. Mohamed MA, Weir MR. Renin angiotensin system inhibitionin the older person: A review. Clin Geriatr Med. 2009;25:245-257.
10. Kithas PA, Supiano MA. Practical recommendations fortreatment of hypertension in older patients. Vasc Health RiskManag. 2010;6:561-569.
11. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosteroneproducing adenoma by measuring plasma renin activity:Results in hypertensive patients. Arch Intern Med. 1981;141:1589-1593.
12. Moneva MH, Gomez-Sanchez CE. Establishing a diagnosisof primary aldosteronism. Curr Opin Endocrinol Diabetes. 2001;8:124-129.
13. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: A clue toefficient treatment. J Hypertens. 2004;22:2217-2226.
14. Tomaschitz A, Maerz W, Pilz S, Ritz E, Scharnagl H, RennerW, et al. Aldosterone/renin ratio determines peripheral andcentral blood pressure values over a broad range. J Am CollCardiol. 2010;55:2171-2180.
15. Sowers JR, Whaley-Connell A, Epstein M. Narrative review:The emerging clinical implications of the role of aldosteronein the metabolic syndrome and resistant hypertension. AnnIntern Med. 2009;150:776-783.
16. O' R ourke MF, Frohlich ED. Pulse pressure: Is this a clinicallyuseful risk factor? Hypertension. 1999;34:372-374.
17. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, RifaiN, et al. Serum aldosterone and the incidence of hypertensionin nonhypertensive persons. N Engl J Med. 2004;351:33-41.
18. Duprez D, De Buyzere M, Rietzschel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep. 2000;2:327-334.
19. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, SafarM. Increased carotid wall elastic modulus and fibronectin inaldosterone-salt-treated rats: Effects of eplerenone. Circulation. 2002;106:2848-2853.
20. Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret C, et al. Spironolactone improves carotid artery fibrosisand distensibility in rat post-ischaemic heart failure. J MolCell Cardiol. 2005;39:511-519.
21. Schmidt BM, Schmieder RE. Aldosterone-induced cardiacdamage: Focus on blood pressure independent effects. Am JHypertens. 2003;16:80-86.
22. Park S, Kim JB, Shim CY, Ko YG, Choi D, Jang Y, et al. Theinfluence of serum aldosterone and the aldosterone-reninratio on pulse wave velocity in hypertensive patients. J Hypertens. 2007;25:1279-1283.
23. Kjeldsen SE, Dahl öf B, Devereux RB, Julius S, Aurup P, Edelman J, et al.; LIFE (Losartan Intervention for EndpointReduction) Study Group. Effects of losartan on cardiovascularmorbidity and mortality in patients with isolated systolichypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288:1491-1498.
24. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosteroneblocker eplerenone versus the calcium antagonistamlodipine in systolic hypertension. Hypertension. 2003;41:1021-1026.
25. He J, Klag MJ, Appel LJ, Charleston J, Whelton PK. Therenin-angiotensin system and blood pressure: Differences betweenblacks and whites. Am J Hypertens. 1999; 12:555-562.
26. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, SagarKB, Kaldunski M, et al. Arterial pressure, left ventricularmass, and aldosterone in essential hypertension. Hypertension. 2001;37:845-850